United States MicroRNA Market Size, Share, and COVID-19 Impact Analysis, By Product & Service (Products and Services), By Application (Cardiovascular Disease, Cancer, Neurological Diseases, Immunological Disorder, Infectious Diseases, and Others), By End-User (Academic & Government Research Institutes, Biotechnology & Pharmaceutical Companies, and Others), and US MicroRNA Market Insights, Industry Trend, Forecasts to 2035

USA MicroRNA Market Insights Forecasts to 2035

• The US MicroRNA Market Size Was Estimated at USD 681.14 Million in 2024
• The Market Size is expected to Grow at a CAGR of around 11.80% from 2025 to 2035
• The USA MicroRNA Market Size is Expected to reach USD 2322.82 Million by 2035

According to a research report published by Spherical Insights & Consulting, the US MicroRNA Market Size is Anticipated to reach USD 2322.82 Million by 2035, Growing at a CAGR of 11.80% from 2025 to 2035. The market expansion is attributed to the technological advancements in nucleic acid studies, rising focus on molecular studies in clinical sectors, and rising investments from the government.

Market Overview

The United States microRNA involves the development, commercialization, and utilization of the microRNA-based technologies in detection, diagnostics, therapeutics, research, cancer detection, infectious disease management, and personalized medicine. The majority of eukaryotes, including humans, have microRNA (miRNA), which was first identified in Caenorhabditis elegans. It is estimated to control at least 30% of the genes that code for proteins and make up 1% to 5% of the human genome. Small, non-coding RNA molecules called miRNA. It binds to target mRNA in two different ways to stop the synthesis of proteins. Primary miRNA undergoes a two-step cleavage to produce mature miRNA, which then joins the RISC effector complex. The silencing mechanism is determined by the degree of complementarity between the guide and the mRNA target. MicroRNAs are encoded in regions including exons, introns, and intergenic regions. The increasing prevalence of chronic diseases and miRNA acts as a biomarker for the early detection of diseases, which leads to driving the market growth.

Report Coverage

This research report categorizes the market for the US microRNA market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the US microRNA market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US microRNA market.

Driving Factors

Increasing prevalence of chronic diseases:

The chronic diseases are rising rapidly due to environmental causes, aging populations, and lifestyle choices. MicroRNAs (miRNAs) have become attractive biomarkers for chronic disorders, owing to their influence on biological processes and function in regulating gene expression. Since miRNA dysregulation is frequently linked to particular illnesses, it is a useful marker for prognosis and diagnosis. Researchers are looking into miRNAs as potential diagnostic markers for disorders like myocardial infarction, heart failure, and atherosclerosis. Cardiovascular diseases (CVDs) are one of the major causes of morbidity and mortality in the world. MiRNAs are known to have a part in the initiation and spread of cancer, offering biological markers for early cancer detection and therapeutic approaches. Research on the involvement of miRNAs in metabolic disorders and diabetes has increased as a result of the rise in these conditions.

Extensive usage of microRNA in the pharmaceutical and biotechnology sectors.

The biotechnology and pharmaceutical industries are concentrating on the therapeutic potential of miRNAs, finding disease-specific signatures for new biopharmaceuticals. MiRNAs provide two approaches to precision medicine: they are exploited as therapeutic targets and diagnostic indicators. MiRNA discoveries are being translated into useful applications more quickly owing to strategic partnerships between biotechnology companies, pharmaceutical corporations, and academic institutions. The versatility of miRNA-based medicines in controlling gene expression and providing targeted treatments is drawing interest. In order to assess the safety and effectiveness of miRNA mimics and inhibitors across a range of illnesses, preclinical and clinical experiments are now underway. Additionally, miRNAs are being incorporated into diagnostic systems for early illness monitoring and diagnosis. Hence, the need for microRNA and its technologies is greater in the pharma and biotech fields, which results in the market expansion.

Restraining Factors

The United States microRNA market faces challenges such as high development costs, regulatory obstacles, complicated data interpretation, a lack of clinical validation, and competition from alternative biomarkers.

Market Segmentation

The USA microRNA market share is classified into product & service, application, and end-user.

• The services segment held the largest market share of 56.01% in 2024 and is expected to grow at a significant CAGR during the forecast period.

The US microRNA market is segmented by product & service into products and services. Among these, the services segment held the largest market share of 56.01% in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental expansion is attributed to the growing number of research, clinical applications, and the demand for functional studies, identification, the purification process, and profiling services.

• The cancer segment accounted for the largest share of 36.28% in 2024 and is expected to grow at a significant CAGR during the forecast period.

The US microRNA market is segmented by application into cardiovascular disease, cancer, neurological diseases, immunological disorders, infectious diseases, and others. Among these, the cancer segment accounted for the largest share of 36.28% in 2024 and is expected to grow at a significant CAGR during the forecast period. This is driven by the increasing prevalence of the cancer, growing implementation of next-generation sequencing technologies in cancer detection, and significant use of miRNA diagnostics in cancer treatment.

• The biotechnology & pharmaceutical companies segment accounted for the largest market share of 45.81% in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

The US microRNA market is segmented by end-user into academic & government research institutes, biotechnology & pharmaceutical companies, and others. Among these, the biotechnology & pharmaceutical companies segment accounted for the largest market share of 45.81% in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The segment growth is attributed to the extensive usage of the miRNA in the pharmaceutical and biotechnology companies for the targeting of diseases, modulation of drug response, as biomarkers, drug discovery, and development.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the US microRNA market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• PerkinElmer, Inc.
• GeneCopoeia, Inc.
• Precision Nanosystems
• Thermo Fisher Scientific, Inc
• Cytiva
• NanoString Technologies, Inc
• Synlogic
• AptamiR Therapeutics
• BioGenex
• Others

Recent Developments:

• In April 2025, NeuroSense Therapeutics announced promising findings from its Phase 2b PARADIGM clinical trial, revealing the significant impact of PrimeC, its investigational therapy for ALS, on microRNA modulation. The company is focused on deepening mechanistic insights and identifying miRNA-based biomarkers for predicting treatment response. The Phase 2b PARADIGM data provides a solid foundation for further research into PrimeC's impact on miRNA maturation and other neurodegenerative indications.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the US microRNA market based on the below-mentioned segments:

US MicroRNA Market, By Product & Service

• Products
• Services

US MicroRNA Market, By Application

• Cardiovascular Disease
• Cancer
• Neurological Diseases
• Immunological Disorder
• Infectious Diseases
• Others

US MicroRNA Market, By End-User

• Academic & Government Research Institutes
• Biotechnology & Pharmaceutical Companies
• Others